STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Schedule 13G/A: William Scully Discloses Near-10% Stake in Prothena

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

William P. Scully reports beneficial ownership of 5,351,846 ordinary shares of Prothena Corporation plc, representing approximately 9.94% of the issuer's outstanding shares based on the issuer's reported figure of 53,826,982 shares. The holdings combine direct ownership and interests across investment vehicles, including a direct stake, an LLC, multiple IRAs, trusts and grantor retained annuity trusts.

The filing breaks ownership into 768,000 shares over which Mr. Scully has sole voting and dispositive power and 4,583,846 shares over which he has shared voting and dispositive power, reflecting a mix of individually held shares and positions held through managed or trust arrangements.

Positive

  • Material stake disclosed: Aggregate beneficial ownership of 5,351,846 shares (~9.94%) is clearly reported.
  • Clear breakdown of control: Filing specifies 768,000 shares with sole voting/dispositive power and 4,583,846 with shared power, improving transparency.

Negative

  • None.

Insights

TL;DR: A near-10% stake is material; it signals a significant investor position without an asserted intent to change control.

The filing discloses an aggregate position of 5,351,846 shares (≈9.94%), split between sole and shared voting/dispositive powers. For investors, a holder approaching 10% can be important for shareholder dynamics, potential engagement, and voting outcomes. The certification that the position was not acquired to influence control implies passive or investment-oriented intent, but the size alone makes this an item of interest for governance and possible future disclosures.

TL;DR: The combination of sole and shared control across trusts and funds creates governance complexity despite an asserted non-control intent.

The record shows 768,000 shares with sole power and 4,583,846 shares with shared power due to trusts, IRAs and managed accounts. Shared dispositive or voting power through trust features and substitution rights can complicate clear attribution of influence. Stake concentration near 10% warrants monitoring of any future amendments or coordinated actions that could change governance dynamics.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



SCULLY WILLIAM P
Signature:/s/ Diana L. Hayes
Name/Title:attorney-in-fact
Date:08/13/2025

Comments accompanying signature: Pursuant to a limited power of attorney dated February 13, 2024, a copy of which is on file with the Commission

FAQ

How many Prothena (PRTA) shares does William P. Scully beneficially own?

The filing states Mr. Scully may be deemed the beneficial owner of 5,351,846 ordinary shares of Prothena.

What percentage of Prothena does Scully's stake represent?

The disclosed shares represent approximately 9.94% of the issuer's outstanding shares based on 53,826,982 shares outstanding.

How is Scully's voting and dispositive power divided?

He has sole voting/dispositive power over 768,000 shares and shared voting/dispositive power over 4,583,846 shares.

Through which vehicles are the shares held?

Holdings include direct ownership, Manatee Equity Fund LLC, multiple IRAs, various trusts, grantor retained annuity trusts, and another trust with substitution rights.

Does the filing state intent to influence control of Prothena?

The certifying statement declares the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Prothena

NASDAQ:PRTA

PRTA Rankings

PRTA Latest News

PRTA Latest SEC Filings

PRTA Stock Data

600.74M
43.39M
18.66%
79.67%
7.53%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2